The Association Between Hot Flashes and Renal Dysfunction After Androgen Deprivation Therapy With Radiotherapy in Japanese Patients With High-risk Prostate Cancer

Overview

Journal In Vivo

Specialty Oncology

Date 2021 Oct 26

PMID 34697186

Authors

Hiroshi Masuda

Kosuke Mikami

Kotaro Otsuka

Kyokusin Hou

Takahito Suyama

Kazuhiro Araki

Satoko Kojima

Yukio Naya

Affiliations

Soon will be listed here.

Abstract

Background/aim: We investigated the changes in and characteristics of renal function in Japanese patients with high-risk prostate cancer (PCa) who underwent radiotherapy and long-term androgen deprivation therapy (ADT), including those seen after the ADT was discontinued.

Patients And Methods: Among 60 patients who were pathologically diagnosed with PCa and received ADT for 24 months and radiotherapy, 36 patients who underwent treatment for stage B or C PCa were eligible. We assessed renal function using the estimated glomerular filtration rate (eGFR) and investigated the rate of change in the eGFR (ΔeGFR) during and after ADT. Univariate and multivariate logistic analyses were carried out to identify clinical factors that were significantly associated with renal dysfunction at 36 months.

Results: The incidence of renal dysfunction at 36 months was 75% (27/36). Multivariate analysis showed that the presence/absence of HF was an independent predictor of renal dysfunction at 36 months.

Conclusion: Renal function tended to recover after ADT was received for 24 months and subsequently discontinued. The presence/absence of HF represents new and meaningful information for patients receiving ADT, and high-risk PCa patients prior to ADT.

References

Keating N, OMalley A, Freedland S, Smith M . Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?. Eur Urol. 2012; 64(1):159-66. PMC: 3683550. DOI: 10.1016/j.eururo.2012.04.035. View

Dosani M, Morris W, Tyldesley S, Pickles T . The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial. Clin Oncol (R Coll Radiol). 2017; 29(10):696-701. DOI: 10.1016/j.clon.2017.06.009. View

Ahmadi H, Daneshmand S . Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013; 111(4):543-8. DOI: 10.1111/j.1464-410X.2012.11774.x. View

Masuda H, Fujimoto A, Kanesaka M, Hou K, Suyama T, Araki K . Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer. Anticancer Res. 2021; 41(9):4443-4446. DOI: 10.21873/anticanres.15252. View

Braga-Basaria M, Dobs A, Muller D, Carducci M, John M, Egan J . Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006; 24(24):3979-83. DOI: 10.1200/JCO.2006.05.9741. View

Perlmutter M, Lepor H . Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007; 9 Suppl 1:S3-8. PMC: 1831539. View

Sharifi N, Gulley J, Dahut W . Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294(2):238-44. DOI: 10.1001/jama.294.2.238. View

Lapi F, Azoulay L, Niazi M, Yin H, Benayoun S, Suissa S . Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA. 2013; 310(3):289-96. DOI: 10.1001/jama.2013.8638. View

Masuda H, Sugiura M, Hou K, Araki K, Kojima S, Naya Y . Impact of Hypertension on Early Renal Dysfunction in Japanese Prostate Cancer Patients Treated With Androgen Deprivation Therapy. Cancer Diagn Progn. 2022; 1(3):179-183. PMC: 8962788. DOI: 10.21873/cdp.10024. View

10.

Basaria S . Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl. 2008; 29(5):534-9. DOI: 10.2164/jandrol.108.005454. View

11.

Mohler J, Bahnson R, Boston B, Busby J, DAmico A, Eastham J . NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8(2):162-200. DOI: 10.6004/jnccn.2010.0012. View

12.

Braga-Basaria M, Muller D, Carducci M, Dobs A, Basaria S . Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res. 2006; 18(5):494-8. DOI: 10.1038/sj.ijir.3901471. View

13.

Molinari C, Battaglia A, Grossini E, Mary D, Vassanelli C, Vacca G . The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol. 2002; 543(Pt 1):365-72. PMC: 2290490. DOI: 10.1113/jphysiol.2002.022756. View

14.

Charig C, Rundle J . Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology. 1989; 33(3):175-8. DOI: 10.1016/0090-4295(89)90385-3. View

15.

Kambham N, Markowitz G, Valeri A, Lin J, DAgati V . Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001; 59(4):1498-509. DOI: 10.1046/j.1523-1755.2001.0590041498.x. View

16.

Hutchens M, Fujiyoshi T, Komers R, Herson P, Anderson S . Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo. Am J Physiol Renal Physiol. 2012; 303(3):F377-85. PMC: 3774263. DOI: 10.1152/ajprenal.00354.2011. View

17.

Shahinian V, Kuo Y, Freeman J, Orihuela E, Goodwin J . Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005; 103(8):1615-24. DOI: 10.1002/cncr.20955. View

18.

Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K . Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol. 2004; 11(9):735-41. DOI: 10.1111/j.1442-2042.2004.00896.x. View

19.

Kouriefs C, Georgiou M, Ravi R . Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int. 2002; 89(4):379-83. DOI: 10.1046/j.1464-4096.2001.01761.x. View

20.

Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N . Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008; 31(3):433-41. DOI: 10.1291/hypres.31.433. View